SMAD4 as a Predictive Biomarker For Locally Aggressive Phenotype In Resected Pancreas Cancer
Hunter C. Gits(Pediatric Oncology Group), Kenneth W. Merrell(Mayo Clinic), J.B. Ashman(Mayo Clinic Hospital), Amy Tang(University of Southern California), Mark J. Truty(Mayo Clinic in Arizona), Terence T. Sio(The University of Texas MD Anderson Cancer Center), William G. Rule(Mayo Clinic in Arizona), William R. Bamlet(Mayo Clinic), William S. Harmsen(Mayo Clinic), Rondell P. Graham(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), Michael G. Haddock(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Amit Mahipal(Dana-Farber Cancer Institute), Wenduan Ma(Mayo Clinic in Arizona), Dawn Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
International Journal of Radiation Oncology*Biology*Physics
October 23, 2020
Cited by 2
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746